# Cystic Fibrosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/cystic-fibrosis

> 8 upcoming FDA catalysts in cystic Fibrosis: elx/tez/iva (VRTX) on Apr to Jul 2027 (topline data readout); elx/tez/iva (VRTX) on April 2027 (primary completion); elx/tez/iva (VRTX) on Sep to Dec 2027 (topline data readout); elx/tez/iva (VRTX) on September 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 4, 2025 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357)) |
| January 29, 2026 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05153317 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05153317)) |
| mid-2026 | [SION-719 topline data readout](https://sec-api.dev/pdufa/sion-719) | SION | cystic fibrosis | scheduled | "Topline data from this trial are anticipated in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sionfy4q25earningsrelease_.htm)) |
| Oct 2026 to Jan 2027 | [Vx-121/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05444257 (A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05444257)) |
| October 15, 2026 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357?tab=results)) |
| October 2026 | [Vx-121/tez/d-iva primary completion](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | delayed | "NCT05444257 (A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05444257)) |
| Apr to Jul 2027 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05331183 (Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05331183)) |
| April 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05331183 (Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05331183)) |
| Sep to Dec 2027 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT06460506 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06460506)) |
| September 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT06460506 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06460506)) |
| Jul to Oct 2029 | [Vnz/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vnz-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05844449 (Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844449)) |
| July 2029 | [Vnz/tez/d-iva primary completion](https://sec-api.dev/pdufa/vnz-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05844449 (Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-07-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844449)) |
| Jun to Sep 2030 | [Vx-121/tez/d-iva topline data readout](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05422222 (Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05422222)) |
| June 2030 | [Vx-121/tez/d-iva primary completion](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05422222 (Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05422222)) |

## Drugs

- [Elx/tez/iva](https://sec-api.dev/pdufa/elx-tez-iva) (VRTX)
- [SION-719](https://sec-api.dev/pdufa/sion-719) (SION)
- [Vx-121/tez/d-iva](https://sec-api.dev/pdufa/vx-121-tez-d-iva) (VRTX)
- [Vnz/tez/d-iva](https://sec-api.dev/pdufa/vnz-tez-d-iva) (VRTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/cystic-fibrosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cystic Fibrosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/cystic-fibrosis

```bibtex
@misc{secapidev_indications_cystic_fibrosis_20261116,
  title        = {Cystic Fibrosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/cystic-fibrosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_cystic_fibrosis_20261116","title":"Cystic Fibrosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/cystic-fibrosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
